Maria Velez-Yanguas
Pediatric Hematology-Oncology · New Orleans, LANPI 1306869268
Payments from drug & device makers
Across 574 payments — averaging $689.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$257K
- Pfizer$35K
- Sanofi$32K
- CSL Behring$25K
- AstraZeneca$17K
- Jazz Pharmaceuticals Inc.$9K
- plus $21K from 29 others
What the payments were for
- Consulting fees$39,58938%
- Speaking & faculty fees$35,19233%
- Travel & lodging$23,37722%
- Food & beverage$7,2227%
- Education$1000%
- Entertainment$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 359 | $257,499 |
| Pfizer | 17 | $34,528 |
| Sanofi | 25 | $31,678 |
| CSL Behring | 35 | $25,104 |
| AstraZeneca(2 entities) | 13 | $16,533 |
| Jazz Pharmaceuticals Inc. | 4 | $9,193 |
| Octapharma USA, Inc. | 22 | $6,352 |
| Global Blood Therapeutics, Inc. | 7 | $5,623 |
| Day One Biopharmaceuticals | 1 | $3,575 |
| Kedrion Biopharma Inc. | 1 | $2,632 |
| Genetix Biotherapeutics Inc | 9 | $689 |
| Novo Nordisk | 15 | $478 |
| Novartis | 18 | $326 |
| Servier Pharmaceuticals LLC | 13 | $231 |
| BTG International Inc. | 4 | $227 |
| Sobi, Inc | 7 | $214 |
| Incyte Corporation | 1 | $125 |
| Bioverativ Therapeutics Inc. | 1 | $110 |
| Apellis Pharmaceuticals, Inc. | 1 | $81 |
| Y-mabs Therapeutics, Inc. | 2 | $62 |
| HEMA Biologics, LLC | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Emmaus Medical, Inc. | 2 | $43 |
| Bayer | 2 | $41 |
| Fennec Pharmaceuticals, Inc. | 1 | $28 |
| Medunik USA Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Eurofins Viracor, LLC | 1 | $16 |
| Medexus Pharma, Inc. | 1 | $15 |
| USWM, LLC | 1 | $15 |
| Amgen | 1 | $15 |
| Silvergate Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Idelvion$24,219
- REBINYN$10,753
- QFITLIA$10,416
- KOSELUGO$9,660
- HEMGENIX$8,658
- Afstyla$6,761
- OXBRYTA$5,570
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$3,723
- ALTUVIIIO$3,677
- OJEMDA$3,575
- KOATE$2,632
- NUWIQ$2,107
- LYFGENIA$310
- Zynteglo$267
- DEFITELIO$150
- NIKTIMVO$125
- Alhemo$122
- VORAXAZE$115
- ALPROLIX$110
- NovoSeven$106
How this compares
$395,639 in reported general payments places this provider in the 90th percentile of 26 pediatric hematology-oncology providers in Louisiana.
See all pediatric hematology-oncology providers in Louisiana →
Other pediatric hematology-oncology in New Orleans
- Tammuella Chrisentery-SingletonNew Orleans$2.2M
- Lolie YuNew Orleans$283K
- Craig LottermanNew Orleans$211K
- Zachary LeblancNew Orleans$77K
- Renee GardnerNew Orleans$46K
- Robert VasquezNew Orleans$45K
- Dana LeblancNew Orleans$38K
- Pinki PrasadNew Orleans$20K
- Cori MorrisonNew Orleans$1K
- Justin FargeNew Orleans$797
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.